Paul Tudor Jones Autolus Therapeutics PLC Transaction History
Tudor Investment Corp Et Al
- $200 Billion
- Q3 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 206,653 shares of AUTL stock, worth $287,247. This represents 0.0% of its overall portfolio holdings.
Number of Shares
206,653
Previous 106,653
93.76%
Holding current value
$287,247
Previous $243,000
39.09%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding AUTL
# of Institutions
103Shares Held
150MCall Options Held
24.6KPut Options Held
41.9K-
Mak Capital One LLC New York, NY26MShares$36.2 Million6.54% of portfolio
-
Blackstone Inc New York, NY20.5MShares$28.5 Million0.15% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$23.1 Million97.83% of portfolio
-
Armistice Capital, LLC New York, NY15.6MShares$21.7 Million0.39% of portfolio
-
Tfg Asset Management Gp LTD Grand Cayman, E99.5MShares$13.2 Million3.44% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $126M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...